Mr. Gregg Kyle

As a Principal with Burgess Vector, Mr. Kyle brings nearly twenty five years experience in biomedical sciences to client engagements. Seventeen years of this experience has involved transactions ranging from clinical trials agreements, materials transfer, government research contracts, CRADAs, licensing, M&A, and industry research collaborations.

Mr. Kyle's extensive knowledge of the issues surrounding intellectual property is a direct result of the multitude of licensing deals he has successfully negotiated. One of these deals involving the drug Allegra has produced $30 million in fees and royalties for Georgetown University. Mr. Kyle directs business development activity at QB3, a multi-campus University of California institute for technology excellence in systems biology and computational biology. Prior to joining Burgess Vector, he held the positions of Senior Director, Business Development at Rigel Pharmaceuticals and Director of Business Development at Corixa Pharmaceuticals. At both companies, his primary duty was technology scouting and in-licensing. His previous transactional work was in university technology transfer and contracting.

Mr. Kyle has been awarded a Masters Degree in Biology from Wayne State and a Bachelors degree from Hiram College. In addition, his research experience at the Michigan Cancer Foundation and Lombardi Cancer Center resulted in eight publications and two AACR presentations. Mr. Kyle is active in the Association of University Technology Managers and the Licensing Executives Society.